MAY 23, 2019 10:10 PM PDT

Repurposing Cancer Drug for Treating Brain Aneurysms

WRITTEN BY: Nouran Amin

Brain aneurysms is a result of a bulging blood vessel due to a weakness in the blood vessel wall. When the blood passes through the weakened vessel walls, blood pressure will cause a small area to bulge outwards. These bulges can develop anywhere but most commonly in the abdominal aorta and the brain.

Learn more about aneurysms:

Treating a brain aneurysm is a challenge and involves complex surgery that has been attempted in select cases most notably Game of Thrones actress Emilia Clarke who suffered from two aneurysms while filming the series.

Now, new research points to a critical drug class used in the treatment of cancer patients in its potential to be repurposed for treating brain aneurysms. The class of drug is known as 'Receptor tyrosine kinase inhibitors' and can target the genetic basis of brain aneurysm—which involve mutations in the gene PDGFRB.

"This is an extremely exciting discovery which shows how basic lab-derived observations on a genetic level can move into a clinical setting and start making big changes to public healthcare and treatments,” says Mark O'Driscoll, Professor of Human Molecular Genetics at the Genome Damage and Stability Centre at the University of Sussex.

A 3D reconstruction of an angiogram showing the aneurysm circled in red. Credit: University of Sussex

"Our research focused primarily on understanding the genetic and cellular mechanisms underlying a particular type of aneurysm. By finding a new genetic basis in some patients, we were also able to demonstrate that a known cancer drug could counter this genetic basis in most instances. Understanding the genetics behind diseases like this is crucial in identifying possible treatments and next steps -- and that is exactly what our part in this new research has shown. The lead authors and our collaborators on this paper based in the US, are now working on the next stages to test this drug further."

Drug repurposing is not new to research and many studies have attempted to use FDA-approved drugs for the treatment of other disorders. Other drug repurposing stories have been successful with even dangerous drugs like thalidomide for treating leprosy.

"We are now very close to treating these aneurysm patients with PDGFRB variants with specific receptor tyrosine kinase inhibitors,” says lead author of the study, Dr. Manuel Ferreira of the University Of Washington School Of Medicine.

Findings of the study were published in the American Journal of Human Genetics.

Source: University of Sussex

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 16, 2020
Health & Medicine
JAN 16, 2020
Babies in Africa Receive World's First Malaria Vaccine
Would you accept a vaccine that was only 40% effective? For those at risk of malaria, the answer is likely a resounding, "yes!" According to the...
JAN 20, 2020
Cell & Molecular Biology
JAN 20, 2020
Using Modified Red Blood Cells As a Drug Delivery System
For a drug to be effective, it has to get to the right place to exert its impact....
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
China Begins Trials for Antiviral Drug to Tackle Coronavirus
So far, coronavirus has infected over 31,493 people globally, and has killed 638. Although 1,563 people have reportedly recovered, due to its fast-spreadin...
MAR 14, 2020
Chemistry & Physics
MAR 14, 2020
Scientists Developed "Molecular Drills" to Treat Skin Diseases
Molecular machines are small chemical structures that are capable of achieving mechanical tasks that's similar to their macroscopic counterparts, excep...
APR 04, 2020
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native ligand, hepatocyte growth factor...
Loading Comments...